Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 24, 2014, 11:16:03 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 621402
  • Total Topics: 46816
  • Online Today: 242
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: US guidance says that pregnant women should not take nelfinavir  (Read 899 times)

0 Members and 1 Guest are viewing this topic.

Offline newt

  • Member
  • Posts: 3,869
  • the one and original newt
US guidance says that pregnant women should not take nelfinavir
« on: September 11, 2007, 06:13:10 AM »
US guidance says that pregnant women should not take nelfinavir

A “Dear Healthcare Provider” letter has been issued in the US advising that pregnant women should not start an anti-HIV regimen that contains nelfinavir (Viracept), or switch to an alternative regimen if they are already taking the drug. The letter also states that children aged under 16 years should not initiate treatment with nelfinavir.

The letter was issued by Pfizer, who manufacture and market nelfinavir in the US and Canada. In June this year, nelfinavir manufactured in Europe (and distributed to countries around the world) was recalled by Roche after it was discovered that some batches of the drug had been contaminated with excess amount of ethyl methanesulfonate (EMS), large quantities of which have been shown to cancer in rats.

Because of this recall, the US Food and Drug Administration requested that Pfizer introduce new guidance to limit patient exposure to EMS.

Tests on nelfinavir in the US found levels of EMS considerably lower than those that prompted the recall of nelfinavir in Europe.
 
Nevertheless the FDA and Pfizer have agreed interim and long-term EMS exposure levels.

... (bit later it says)

It is thought that children aged between two and 16 years have a threefold increased risk of developing cancer after exposure to EMS, and that infants under this age have an even greater risk. Because of this, Pfizer and the FDA have recommended that, until further notice, children should not start anti-HIV therapy with nelfinavir.

However, for infants and children who are already taking a stable regimen that contains nelfinavir “the FDA and Pfizer agree that the benefit-risk ratio remains favorable and those children may continue to receive Viracept.” <<< huh?

Although there is no evidence that women who took nelfinavir during pregnancy had an increased risk of having a baby with birth defects, the FDA is nevertheless recommending that women should limit their exposure to EMS during pregnancy.

Therefore, pregnant women should not initiate antiretroviral therapy that contains nelfinavir, and pregnant women currently taking nelfinavir should switch to an alternative regimen

- matt
"The object is to be a well patient, not a good patient"

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.